What are the effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients?
The Heart Outcomes Prevention Evaluation Study found that ramipril, an angiotensin-converting-enzyme inhibitor, had a positive effect on cardiovascular events in high-risk patients. Several other studies, such as the Prevention of Events with ACE Inhibition (PEACE) trial, the EUROPA trial, and the Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN), have also found positive effects of ACE inhibitors, such as perindopril and benazepril, on cardiovascular events in patients with chronic kidney disease, chronic stable coronary disease, and IgA nephropathy, respectively. However, a 2010 study found that ACE inhibitors had no significant effect on composite renal endpoints. 